Your browser doesn't support javascript.
loading
End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.
Carlozzi, Noelle E; Boileau, Nicholas R; Paulsen, Jane S; Perlmutter, Joel S; Lai, Jin-Shei; Hahn, Elizabeth A; McCormack, Michael K; Nance, Martha A; Cella, David; Barton, Stacey K; Downing, Nancy R.
Afiliação
  • Carlozzi NE; Department of Physical Medicine and Rehabilitation, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building NCRC B14, Room G216, Ann Arbor, MI, 8109-2800, USA. carlozzi@med.umich.edu.
  • Boileau NR; Department of Physical Medicine and Rehabilitation, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building NCRC B14, Room G216, Ann Arbor, MI, 8109-2800, USA.
  • Paulsen JS; Department of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA.
  • Perlmutter JS; Department of Neurology, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA.
  • Lai JS; Department of Psychological and Brain Sciences, The University of Iowa, Iowa City, IA, USA.
  • Hahn EA; Neurology, Radiology, Neuroscience, Physical Therapy, Occupational Therapy, Washington University in St. Louis, St. Louis, MO, USA.
  • McCormack MK; Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
  • Nance MA; Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
  • Cella D; Department of Pathology, Rowan University-SOM, Stratford, NJ, USA.
  • Barton SK; Department of Psychiatry, Rutgers University, RWJMS, Piscataway, NJ, USA.
  • Downing NR; Struthers Parkinson's Center, Golden Valley, MN, USA.
J Neurol ; 266(10): 2406-2422, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31190171
BACKGROUND AND PURPOSE: Huntington disease (HD) is a progressive neurodegenerative disorder. There are no HD-specific measures to assess for end-of-life (EOL) preferences that have been validated for clinical use. The purpose of this study is to demonstrate reliability and validity of three HD-specific EOL measures for use in and clinical research settings. METHODS: We examined internal reliability, test-retest reliability, floor and ceiling effects, convergent and discriminant validity, known groups' validity, measurement error, and change over time to systematically examine reliability and validity of the HDQLIFE EOL measures. RESULTS: Internal consistency and test-retest reliability were > 0.70. The measures were generally free of floor and ceiling effects and measurement error was minimal. Convergent and discriminant validity were consistent with well-known constructs in the field. Hypotheses for known groups validity were partially supported (there were generally group differences for the EOL planning measures, but not for meaning and purpose or concern with death and dying). Measurement error was acceptable and there were minimal changes over time across the EOL measures. CONCLUSIONS: Results support the clinical utility of the HDQLIFE EOL measures in persons with HD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Qualidade de Vida / Assistência Terminal / Atitude Frente a Morte / Doença de Huntington / Planejamento Antecipado de Cuidados Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Qualidade de Vida / Assistência Terminal / Atitude Frente a Morte / Doença de Huntington / Planejamento Antecipado de Cuidados Idioma: En Ano de publicação: 2019 Tipo de documento: Article